此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Impact of a Pharmacist-led Patient-centred Care Intervention Along With Text-Message Reminders, on the Management of Newly Diagnosed Tubercular Patients: a Protocol for a Randomized Controlled Trial'.

2022年6月24日 更新者:Farman Ullah Khan、Health Science Center of Xi'an Jiaotong University
This project aims to standardize the management of "Pharmaceutical care with the two-way text messages and incentive for mobile usage during the treatment for tuberculosis patients, to improve the outcomes and compliance, reduce the risk of transmission and to evaluate the patient perspective in terms of their quality of life, shared decision making and satisfaction with services provided.

研究概览

地位

完全的

详细说明

Tuberculosis (TB) remains a top ten leading cause of death globally despite it being a largely curable disease. New effective treatment supervision strategies are needed particularly in low-resource high TB burden settings and a potential solution is in the hands of nearly every patient - a mobile phone. Modern modular design mobile phone software applications ("apps") hold great promise to address this unmet need. Current technologies allow for rapid design modification based on end-user needs, implementation of native operating system (e.g., Android) versions for users with inconsistent internet access, and the integration of the patients' experiences with electronic health records using industry standards. Apps can perform multiple functions (e.g., automated reminders, symptom tracking, secure messaging, and multi-media education). Another strategy is pharmaceutical care which is utilized to enhance TB treatment compliance along with usage of mobile technologies, where clinical pharmacists provide patient education to improve the patient's knowledge on the disease and medication use and address the patient's drug-related problems. The use of a pharmaceutical care model to improve treatment outcomes and enhance adherence is on the rise in healthcare organizations. At the first visit, the clinical pharmacist provides a mobile phone number and encourages patients to contact them anytime if they need any consultation on the TB treatment. Patients will make prior arrangements with a study pharmacist to determine a convenient meeting place. These meetings will continue until treatment completion. To our knowledge, worldwide there has only been no randomized controlled trial (RCT) which has described the use of both pharmaceutical care model and two-way Short Message Service (SMS) communication with financial incentives (mobile money transfer cover healthcare costs related to SMS charges) to improve treatment outcomes. To find out both the pharmaceutical care model and two-way SMS communication with financial incentives would be helpful for TB patients in Pakistan. Therefore investigator aimed a study, to find out the effectiveness of trial gauged with the impact of the suggested model on the improved adherence, treatment completion, health-related quality of life and satisfaction with TB care.

研究类型

介入性

注册 (实际的)

450

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

      • Islamabad、巴基斯坦、46000
        • Pakistan institute of medical sciences Islamabad

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 至 78年 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Men and women
  • Newly bacteriologically confirmed TB case (less than a month since diagnosis). This restriction (not more than one-month treatment) does not refer to patients whose most recent treatment outcome was a failure and who were assigned to a new treatment regimen.
  • Own a mobile phone which operates on a telecom provider supported by our SMS platform
  • Know how to and are able to receive SMS messages or Phone Call (Caretaker want to participate in case original patient do not participate)
  • An address or residence location that is readily accessible for visiting, and willingness to inform the study team of any change of address during the treatment and follow-up period.
  • No plans to move out of the catchment areas of the participating TB program sites within 9 months of enrollment.
  • Facilities must have at least one TB doctor and one TB nurse available within the facility.
  • Willingness to comply with study procedures and provide written informed consent prior to study enrollment.

Exclusion Criteria:

  • Diagnosis is extra-pulmonary TB
  • Currently enrolled in a clinical trial that prohibits enrollment in another study. Patients are leaving the area within the next six months.
  • Patients are known at the start of treatment to require the treatment longer than it is recommended TB Management Guidelines for the appropriate type of TB.
  • Previous history of TB, multidrug-resistant (MDR) or extensively drug-resistant (XDR) TB.
  • Very ill patient's cognitive or physical disability that prevents full participation in the study such as vision, hearing, physically challenged, inability to swallow medications and unconscious Unable to answer questions.
  • Pregnant females (treatment of TB infection will be deferred)
  • Patients who are receiving treatment from private clinics (Who are not registered in the government TB sectors and they seek are form private health care facilities.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:卫生服务研究
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:干预组

新的管理模式干预:药学服务 最近的策略是药学服务,即医院提供及时的患者教育、药物不良反应的监测和管理、识别其他药物相关问题以及临床药师对治疗依从性的评估。 在第一次就诊时,临床药师会提供手机号码,并鼓励患者在需要任何结核病治疗咨询时随时联系他们。

每天使用手机进行结核病治疗的短信服务和电话将支持药学服务。 结核病患者或家属在整个门诊结核病治疗阶段每天晚上(周日除外)都会接到电话,以确保患者服用结核病医生开具的药物并收集有关治疗依从性和可能出现的副作用的信息。

New management mode intervention: Pharmaceutical care

  • SMS text messages and Phone Calls
  • Behavioural Educational leaflet
  • Self-Administered Therapy A financial incentive for mobile use
其他名称:
  • 药学服务、移动文本、移动使用的经济激励
无干预:无干预组。
纳入对照组的治疗组将接受世界卫生组织推荐的传统-临床直接观察治疗(DOT)和常规治疗组(6个月治疗方案);由医疗保健专业人员提供的常规健康教育。

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
TB treatment success rates
大体时间:6-9 Months
TB treatment success rates defined by the World Health Organization. The investigators will compare clinically reported treatment outcomes between the intervention and control groups.
6-9 Months
Adherence to treatment among drug-sensitive tuberculosis patients self reported and clinical record will checked for the follow up visits and drug taken
大体时间:6-9 Months
Adherence Assessed daily from date of randomization until the date of a documented treatment outcome, up to 24 months after study enrollment date.Counting the number of administered pills, adequate adherence is more than 80% of administered pills.The measure adherence in TB patients for these determinations, we will measure patients' adherence via combined adherence endpoint consisting of Morisky Medication Adherence Scale and pill count rate.
6-9 Months

次要结果测量

结果测量
措施说明
大体时间
Health related Quality of Life of TB patients
大体时间:6-9 Months
At baseline and upon completion of the treatment. To measure HRQoL (Health related Quality of Life) Revalidated data assortment tool European Quality of Life Scale EQ 5D 3L
6-9 Months
Lost To Follow
大体时间:6-9 Months
Lost to follow up or Treatment defaulters patients will be recorded from TB registers upon completion of the treatment
6-9 Months
Patient satisfaction questionnaire
大体时间:6-9 Months
At baseline and upon completion of the treatment. Satisfaction with information can be assessed with the satisfaction with information about medicines scale along with the Beliefs about medicines questionnaire.
6-9 Months

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 学习椅:Yu Fang, Phd、Health Science Center of Xi'an Jiaotong University
  • 研究主任:Amjad Khan, Phd、Quaid i Azam University Islamabad

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2020年9月1日

初级完成 (实际的)

2021年12月30日

研究完成 (实际的)

2021年12月30日

研究注册日期

首次提交

2020年11月15日

首先提交符合 QC 标准的

2020年11月19日

首次发布 (实际的)

2020年11月27日

研究记录更新

最后更新发布 (实际的)

2022年6月29日

上次提交的符合 QC 标准的更新

2022年6月24日

最后验证

2022年6月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

未定

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅